Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
Personalized Medicine Progressing in Premenopausal Breast Cancer
April 17th 2019Joyce A. O’Shaughnessy, MD, discusses the clinical implications of the TEXT and SOFT trials for women with premenopausal HR-positive, HER2-negative breast cancer, as well as unanswered questions that remain with adjuvant endocrine therapy.
Read More
Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer
April 16th 2019Mariana Chavez Mac Gregor, MD, MSc, discusses the optimal applications of these assays in patients with early-stage, HR-positive/HER2-negative breast cancer and shed light on the overall outlook of personalized medicine in this setting.
Read More
Frontline Maintenance Efforts Evolve in Advanced Ovarian Cancer
April 11th 2019Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.
Read More
Frontline Approaches Fine-Tuned in Newly Diagnosed Ovarian Cancer
April 6th 2019Paul Sabbatini, MD, clarifies where the field stands regarding the use of bevacizumab, intraperitoneal therapy, and a 3-week dosing schedule of chemotherapy versus a weekly dose-dense regimen in the frontline setting of newly diagnosed ovarian cancer.
Read More
Immunotherapy Shakes Up Gastric/GEJ Cancer Space, Alongside Angiogenic, Cytotoxic Agents
April 4th 2019J. Stuart Salmon, MD, highlights first-, second-, and third-line treatment options for patients with gastric and gastroesophageal cancer following recent clinical trial findings and regulatory approvals.
Read More
Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer
March 29th 2019The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.
Read More
The use of prophylactic cranial irradiation failed to demonstrate a statistically significant improvement in overall survival over observation in patients with locally advanced stage III non–small cell lung cancer; however, the modality did improve disease-free survival and decreased the risk of brain metastasis.
Read More
HER2+ Breast Cancer Paradigm Slated to Expand With Novel Therapies
March 26th 2019Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.
Read More
Using Recurrence Risk to Tailor Treatment in HR+/HER2- Breast Cancer
March 25th 2019Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.
Read More
Leveraging Limited Data in Metastatic Pancreatic Cancer
March 22nd 2019Damian Laber, MD, provides a brief history of the trials that led to current frontline and second-line standards for patients with metastatic pancreatic cancer and shares his hope for the future of the treatment paradigm.
Read More
Childhood Cancer Substantially Underdiagnosed Worldwide
March 21st 2019Childhood cancer is significantly underdiagnosed—especially in south Asia and sub-Saharan Africa—underscoring the need for stronger health systems and the expansion of universal health coverage, according to an analysis published in Lancet Oncology.
Read More